PER 3.57% 8.7¢ percheron therapeutics limited

Waiting for update- soon Imo+dyor. ATL1101 ATL1101 is a second...

  1. 8,040 Posts.
    lightbulb Created with Sketch. 1823
    Waiting for update- soon
    Imo+dyor.

    ATL1101

    ATL1101 is a second generation antisense drug that targets the insulin-like growth factor I receptor, and has been shown in previously conducted animal studies to suppress human prostate tumour growth.

    The drug has potential applications in various other cancers as well as indications in certain eye diseases, where second generation antisense drugs have shown clinical benefits.

    ATL1101 is potentially positioned to move into clinical development in prostate cancer patients.
 
watchlist Created with Sketch. Add PER (ASX) to my watchlist
(20min delay)
Last
8.7¢
Change
0.003(3.57%)
Mkt cap ! $78.43M
Open High Low Value Volume
8.4¢ 8.7¢ 8.4¢ $72.99K 855.8K

Buyers (Bids)

No. Vol. Price($)
2 452608 8.4¢
 

Sellers (Offers)

Price($) Vol. No.
8.7¢ 398595 1
View Market Depth
Last trade - 16.10pm 30/08/2024 (20 minute delay) ?
PER (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.